SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
SOPHiA GENETICS (Nasdaq: SOPH) will release first quarter 2026 financial results before U.S. markets open on Tuesday, May 5, 2026.
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) will release first quarter 2026 financial results before U.S. markets open on Tuesday, May 5, 2026. A conference call to discuss results and business outlook begins at 8:00 a.m. EDT / 2:00 p.m. CET and will be webcast live.
A replay of the webcast will be available on the company's investor relations website after the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – SOPH
On Apr 21, the day this news came out, SOPH closed 1.35% below the previous close.
Data tracked by StockTitan Argus for the Apr 21 session.
Key Figures
- Q4 2025 revenue
- $21.7M
- Q4 2025, +22% YoY
- FY 2025 revenue
- $77.3M
- Full-year 2025, +19% YoY
- Q4 revenue growth
- 22%
- Q4 2025 YoY revenue growth
- FY revenue growth
- 19%
- Full-year 2025 YoY revenue growth
- Adjusted gross margin
- 74.2%
- Full-year 2025
- IFRS net loss
- $79.0M
- Full-year 2025
- 2026 revenue guidance
- $92M–$94M
- Company guidance for 2026 revenue
- Warrant exercise price
- $5.1829
- Exercise price for 75,000 F-3 registered shares
Previous Earnings date Reports
-
Announced Q4 and full-year 2025 results date with webcast conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
f-3 regulatory
rule 10b5-1 financial
form 144 regulatory
form 4 regulatory
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform that analyzes complex multimodal data – including genomics, radiomics, clinical, biological, and digital pathology data – to generate real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-to-announce-financial-results-for-first-quarter-2026-on-may-5-2026-302743779.html
SOURCE SOPHiA GENETICS
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.